Loading
companiesCompany
Cipla
The Mumbai generics maker famous for a one-dollar-a-day HIV regimen, which sells oncology generics across India and Africa and in 2026 partnered with ImmunoACT to take Indian CAR-T therapy to Africa.
Overview
Cipla was founded in Mumbai in 1935 by Khwaja Abdul Hamied and is India's third-largest drug producer. Its reputation rests on the early-2000s antiretroviral combination it sold for about 300 dollars a year against 12,000 dollars for the branded regimen, and it has applied the same approach to oncology generics and biosimilars for India and emerging markets. In 2026 ImmunoACT announced a collaboration with Cipla to distribute NexCAR19 in South Africa, Algeria and Morocco, the first export of an Indian CAR-T therapy.
Headquarters
Mumbai, IN
Scorecard
All companies#336of 1244 companies, score 11
- approved products +6
- targets +2
- modalities +2
- regions +1
1 approved, 0 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Type
Large pharma · CIPLA.NS
Stage
Public
Website
Founded
1935
ApprovedCAR-T (CD19, humanised)
Talicabtagene autoleucel · NexCAR19
India's first home-grown CAR-T cell therapy, approved in 2023 for relapsed leukaemia and lymphoma, made in Mumbai for roughly a tenth of what the same kind of treatment costs in the US.
Similar pages
- IdeaPublic-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000
Shares Talicabtagene autoleucel, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Most of the world has almost no cancer care, CAR-T cell therapy.
- CompanyDr. Reddy's Laboratories
Shares Oral solid dose manufacturing (tablets and capsules), Small-molecule API synthesis, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.
- PersonRahul Purwar
Shares ImmunoACT, Talicabtagene autoleucel, Most of the world has almost no cancer care, CAR-T cell therapy.
- IdeaA non-profit manufacturer for generic cancer drugs in chronic shortage
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care, Cytotoxic chemotherapy.
- CompanyNatco Pharma
Shares Nexavar compulsory licence (India, 2012), Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
- CompanyIntas Pharmaceuticals (Accord Healthcare)
Shares Oral solid dose manufacturing (tablets and capsules), Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Cytotoxic chemotherapy.
- IdeaA joint price negotiation bloc for middle-income countries, modelled on Beneluxa
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
- IdeaGrant extra exclusivity only in exchange for binding low prices in poorer countries
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
fronts
technologies
drugs
ApprovedCAR-T (CD19, humanised)
Talicabtagene autoleucel · NexCAR19